Delivery Order SPE2DB20D9214-SPE2DB26FD4QZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,746.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $24,084.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 19, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a $27,331.66 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls...
- The Defense Logistics Agency awarded a delivery order valued at $36,229.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is firm fixed-price with an ultimate completion date of October 16, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- The Defense Logistics Agency awarded a delivery order valued at $18,149.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. The award represents a discrete purchase order issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,289.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 12, 2025. The delivery order covers Prolastin C (1,000 mg/20 ml vials), a therapeutic pharmaceutical product, with an ultimate completion date of October 3, 2025. This award utilizes a firm fixed-price contract type with no set-aside designation, allowing DMS Pharmaceutical Group to...
- The Defense Logistics Agency awarded a $18,273.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB26FD4QZDelivery Order
The Defense Logistics Agency awarded a $17,746.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract, with an ultimate completion date of November 19, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain and specializes in distributing comprehensive pharmaceutical products and medical consumables to the Department of Defense and other federal agencies. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded in November 2025, carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The PPV-G GEN V program represents part of a broader $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical and medical supply support for Department of Defense healthcare operations globally, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors serving military healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 10/28/25 |